HOOKIPA Gets FDA Nod For Initial-Stage Prostate Cancer Study
The U.S. Food and Drug Administration (FDA) has accepted HOOKIPA Pharma’s (NASDAQ: HOOK) Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.